Guidance A-Z — D
153 guidance documents beginning with D.
d-Nav insulin management app for type 2 diabetes
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
Danis stent for acute oesophageal variceal bleeding
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin for treating chronic kidney disease
Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daridorexant for treating long-term insomnia
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Darvadstrocel for treating complex perianal fistulas in Crohn's disease
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea
Decision making and mental capacity
Decision-making and mental capacity
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults
Deep brain stimulation for intractable trigeminal autonomic cephalalgias
Deep brain stimulation for refractory chronic pain syndromes (excluding headache)
Deep brain stimulation for refractory epilepsy in adults
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease)
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy
Degarelix for treating advanced hormone-dependent prostate cancer
Delgocitinib for treating moderate to severe chronic hand eczema
Delirium in adults
Delirium: prevention, diagnosis and management in hospital and long-term care
Dementia
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset
Dementia: assessment, management and support for people living with dementia and their carers
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)
Depression in adults
Depression in adults with a chronic physical health problem: recognition and management
Depression in adults: treatment and management
Depression in children and young people
Depression in children and young people: identification and management
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M
Desflurane for maintenance of anaesthesia
Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems)
Deucravacitinib for treating moderate to severe plaque psoriasis
Developing and updating local formularies
Developmental follow-up of children and young people born preterm
Developmental follow-up of children and young people born preterm
Devices for remote monitoring of Parkinson's disease
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexcom G6 for real-time continuous glucose monitoring
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Diabetes in children and young people
Diabetes in pregnancy
Diabetes in pregnancy: management from preconception to the postnatal period
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)
Diabetic foot problems: prevention and management
Diabetic retinopathy: management and monitoring
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management
Difelikefalin for treating pruritus in people having haemodialysis
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment
Digital platforms to support cardiac rehabilitation: early value assessment
Digital self-help for eating disorders: early value assessment
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD)
Digital technologies for delivering multidisciplinary weight-management services: early value assessment
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment
Digital technologies for managing non-specific low back pain: early value assessment
Digital technologies for the detection of melanoma
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment
Digital technologies to support self-management of asthma: early-use assessment
Digital technologies to support self-management of COPD: early value assessment
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Digitally enabled therapies for adults with anxiety disorders: early value assessment
Digitally enabled therapies for adults with depression: early value assessment
Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
Danis stent for acute oesophageal variceal bleeding
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin for treating chronic kidney disease
Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daridorexant for treating long-term insomnia
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Darvadstrocel for treating complex perianal fistulas in Crohn's disease
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea
Decision making and mental capacity
Decision-making and mental capacity
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults
Deep brain stimulation for intractable trigeminal autonomic cephalalgias
Deep brain stimulation for refractory chronic pain syndromes (excluding headache)
Deep brain stimulation for refractory epilepsy in adults
Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease)
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy
Degarelix for treating advanced hormone-dependent prostate cancer
Delgocitinib for treating moderate to severe chronic hand eczema
Delirium in adults
Delirium: prevention, diagnosis and management in hospital and long-term care
Dementia
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset
Dementia: assessment, management and support for people living with dementia and their carers
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)
Depression in adults
Depression in adults with a chronic physical health problem: recognition and management
Depression in adults: treatment and management
Depression in children and young people
Depression in children and young people: identification and management
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M
Desflurane for maintenance of anaesthesia
Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems)
Deucravacitinib for treating moderate to severe plaque psoriasis
Developing and updating local formularies
Developmental follow-up of children and young people born preterm
Developmental follow-up of children and young people born preterm
Devices for remote monitoring of Parkinson's disease
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexcom G6 for real-time continuous glucose monitoring
Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Diabetes in children and young people
Diabetes in pregnancy
Diabetes in pregnancy: management from preconception to the postnatal period
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)
Diabetic foot problems: prevention and management
Diabetic retinopathy: management and monitoring
Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management
Difelikefalin for treating pruritus in people having haemodialysis
Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain
Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment
Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment
Digital platforms to support cardiac rehabilitation: early value assessment
Digital self-help for eating disorders: early value assessment
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD)
Digital technologies for delivering multidisciplinary weight-management services: early value assessment
Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment
Digital technologies for managing non-specific low back pain: early value assessment
Digital technologies for the detection of melanoma
Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment
Digital technologies to support self-management of asthma: early-use assessment
Digital technologies to support self-management of COPD: early value assessment
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Digitally enabled therapies for adults with anxiety disorders: early value assessment
Digitally enabled therapies for adults with depression: early value assessment
Dimethyl fumarate for treating moderate to severe plaque psoriasis
12